Diagnostic Microbiology & Infectious Disease
Volume 67, Issue 1 , Pages 61-69 , May 2010

Evaluation of a new third-generation ARCHITECT rHTLV-I/II assay for blood screening and diagnosis

  • Hans-Peter Kapprell

      Affiliations

    • Abbott GmbH and Co. KG, 65205 Wiesbaden-Delkenheim, Germany
    • Corresponding Author InformationCorresponding author. Abbott GmbH & Co. KG, Max-Planck-Ring 2, 65205 Wiesbaden-Delkenheim, Germany. Tel.: +49-6122-58-1409; fax: +49-6122-58-1473.
    • Both authors contributed equally.
    • ,
  • Myriam Stieler

      Affiliations

    • Abbott GmbH and Co. KG, 65205 Wiesbaden-Delkenheim, Germany
    • Both authors contributed equally.
    • ,
  • Michael Oer

      Affiliations

    • Abbott GmbH and Co. KG, 65205 Wiesbaden-Delkenheim, Germany
    • ,
  • Andreas Goller

      Affiliations

    • Abbott GmbH and Co. KG, 65205 Wiesbaden-Delkenheim, Germany
    • ,
  • Michael Hausmann

      Affiliations

    • Abbott GmbH and Co. KG, 65205 Wiesbaden-Delkenheim, Germany
    • ,
  • Gerald Schochetman

      Affiliations

    • Abbott Diagnostics, Abbott Park, IL 60064, USA
    • ,
  • Sushil G. Devare

      Affiliations

    • Abbott Diagnostics, Abbott Park, IL 60064, USA
    • ,
  • X. Qiu

      Affiliations

    • Abbott Diagnostics, Abbott Park, IL 60064, USA

Received 30 October 2009 ,Accepted 22 December 2009.

References 

  1. Andersson S, Gessain A, Taylor GP. Pooling of samples for seroepidemiological surveillance of human T-cell lymphotropic virus types I and II. Virus Res. 2001;78:101–106
  2. Andersson S, Thorstensson R, Ramirez KG, Krook A, von SM, Dias F, et al. Comparative evaluation of 14 immunoassays for detection of antibodies to the human T-lymphotropic virus types I and II using panels of sera from Sweden and West Africa. Transfusion. 1999;39:845–851
  3. Araujo A, Hall WW. Human T-lymphotropic virus type II and neurological disease. Ann. Neurol. 2004;56:10–19
  4. Blattner WA, Takatsuki K, Gallo RC. Human T-cell leukemia–lymphoma virus and adult T-cell leukemia. JAMA. 1983;250:1074–1080
  5. Burgisser P, Simon F, Wernli M, Wust T, Beya MF, Frei PC. Multicenter evaluation of new double-antigen sandwich enzyme immunoassay for measurement of anti-human immunodeficiency virus type 1 and type 2 antibodies. J. Clin. Microbiol. 1996;34:634–637
  6. Calattini S, Chevalier SA, Duprez R, Afonso P, Froment A, Gessain A, et al. Human T-cell lymphotropic virus type 3: complete nucleotide sequence and characterization of the human tax3 protein. J. Virol. 2006;80:9876–9888
  7. de Araujo AC, Casseb JS, Neitzert E, de Souza ML, Mammano F, Del MA, et al. HTLV-I and HTLV-II infections among HIV-1 seropositive patients in Sao Paulo, Brazil. Eur. J. Epidemiol. 1994;10:165–171
  8. Dodd RY, Notari EP, Stramer SL. Current prevalence and incidence of infectious disease markers and estimated window-period risk in the American Red Cross blood donor population. Transfusion. 2002;42:975–979
  9. Gallarda JL, Henrard DR, Liu D, Harrington S, Stramer SL, Valinsky JE, et al. Early detection of antibody to human immunodeficiency virus type 1 by using an antigen conjugate immunoassay correlates with the presence of immunoglobulin M antibody. J. Clin. Microbiol. 1992;30:2379–2384
  10. Gessain A, Barin F, Vernant JC, Gout O, Maurs L, Calender A, et al. Antibodies to human T-lymphotropic virus type-I in patients with tropical spastic paraparesis. Lancet. 1985;2:407–410
  11. Gessain A, Gout O. Chronic myelopathy associated with human T-lymphotropic virus type I (HTLV-I). Ann. Intern. Med. 1992;117:933–946
  12. Gessain A, Mauclere P, Froment A, Biglione M, Le Hesran JY, Tekaia F, et al. Isolation and molecular characterization of a human T-cell lymphotropic virus type II (HTLV-II), subtype B, from a healthy Pygmy living in a remote area of Cameroon: an ancient origin for HTLV-II in Africa. Proc. Natl. Acad. Sci. U. S. A. 1995;92:4041–4045
  13. Hadlock KG, Goh CJ, Bradshaw PA, Perkins S, Lo J, Kaplan JE, et al. Delineation of an immunodominant and human T-cell lymphotropic virus (HTLV)-specific epitope within the HTLV-I transmembrane glycoprotein. Blood. 1995;86:1392–1399
  14. Hall WW, Ishak R, Zhu SW, Novoa P, Eiraku N, Takahashi H, et al. Human T lymphotropic virus type II (HTLV-II): epidemiology, molecular properties, and clinical features of infection. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 1996;13(Suppl 1):S204–S214
  15. Hino S, Yamaguchi K, Katamine S, Sugiyama H, Amagasaki T, Kinoshita K, et al. Mother-to-child transmission of human T-cell leukemia virus type-I. Jpn. J. Cancer Res. 1985;76:474–480
  16. Hinuma Y, Nagata K, Hanaoka M, Nakai M, Matsumoto T, Kinoshita KI, et al. Adult T-cell leukemia: antigen in an ATL cell line and detection of antibodies to the antigen in human sera. Proc. Natl. Acad. Sci. U. S. A. 1981;78:6476–6480
  17. Hjelle B, Appenzeller O, Mills R, Alexander S, Torrez-Martinez N, Jahnke R, et al. Chronic neurodegenerative disease associated with HTLV-II infection. Lancet. 1992;339:645–646
  18. Horal P, Hall WW, Svennerholm B, Lycke J, Jeansson S, Rymo L, et al. Identification of type-specific linear epitopes in the glycoproteins gp46 and gp21 of human T-cell leukemia viruses type I and type II using synthetic peptides. Proc. Natl. Acad. Sci. U. S. A. 1991;88:5754–5758
  19. Inaba S, Okochi K, Sato H, Fukada K, Kinukawa N, Nakata H, et al. Efficacy of donor screening for HTLV-I and the natural history of transfusion-transmitted infection. Transfusion. 1999;39:1104–1110
  20. Jacobson S, Lehky T, Nishimura M, Robinson S, McFarlin DE, Dhib-Jalbut S. Isolation of HTLV-II from a patient with chronic, progressive neurological disease clinically indistinguishable from HTLV-I–associated myelopathy/tropical spastic paraparesis. Ann. Neurol. 1993;33:392–396
  21. Ji Y, Zhuang W, Liu FR, Zheng P, and Zheng ZW (2008) Prevalence Status of HTLV infection in Chinese blood donors. Vox Sang 95(Suppl. 1):577. (Abstract).
  22. Kalyanaraman VS, Sarngadharan MG, Robert-Guroff M, Miyoshi I, Golde D, Gallo RC. A new subtype of human T-cell leukemia virus (HTLV-II) associated with a T-cell variant of hairy cell leukemia. Science. 1982;218:571–573
  23. Karhumaniki P, Wessberg S, Tuomi K, Palomäki P, Bajzik O, and Laitinen H (2008) First year experience of the Elite System in serological screening at the Finnish Red Cross Blood Service. Vox Sang 95(Suppl. 1):632. (Abstract).
  24. LaGrenade L, Hanchard B, Fletcher V, Cranston B, Blattner W. Infective dermatitis of Jamaican children: a marker for HTLV-I infection. Lancet. 1990;336:1345–1347
  25. Lee H, Swanson P, Shorty VS, Zack JA, Rosenblatt JD, Chen IS. High rate of HTLV-II infection in seropositive i.v. drug abusers in New Orleans. Science. 1989;244:471–475
  26. Manns A, Hisada M, La GL. Human T-lymphotropic virus type I infection. Lancet. 1999;353:1951–1958
  27. Miyoshi I, Kubonishi I, Yoshimoto S, Akagi T, Ohtsuki Y, Shiraishi Y, et al. Type C virus particles in a cord T-cell line derived by co-cultivating normal human cord leukocytes and human leukaemic T cells. Nature. 1981;294:770–771
  28. Morgan OS, Rodgers-Johnson P, Mora C, Char G. HTLV-1 and polymyositis in Jamaica. Lancet. 1989;2:1184–1187
  29. Nishioka K, Maruyama I, Sato K, Kitajima I, Nakajima Y, Osame M. Chronic inflammatory arthropathy associated with HTLV-I. Lancet. 1989;1:441
  30. Osame M, Usuku K, Izumo S, Ijichi N, Amitani H, Igata A, et al. HTLV-I associated myelopathy, a new clinical entity. Lancet. 1986;1:1031–1032
  31. Palker TJ, Tanner ME, Scearce RM, Streilein RD, Clark ME, Haynes BF. Mapping of immunogenic regions of human T cell leukemia virus type I, (HTLV-I) gp46 and gp21 envelope glycoproteins with env-encoded synthetic peptides and a monoclonal antibody to gp46. J. Immunol. 1989;142:971–978
  32. Poiesz BJ, Ruscetti FW, Gazdar AF, Bunn PA, Minna JD, Gallo RC. Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma. Proc. Natl. Acad. Sci. U. S. A. 1980;77:7415–7419
  33. Poiesz BJ, Ruscetti FW, Reitz MS, Kalyanaraman VS, Gallo RC. Isolation of a new type C retrovirus (HTLV) in primary uncultured cells of a patient with Sezary T-cell leukaemia. Nature. 1981;294:268–271
  34. Politis C (2008) The changing epidemiology of HTLV I/II infection in Greece in the period 1987–2007. Vox Sang 95(Suppl. 1):601. (Abstract).
  35. Proietti FA, Carneiro-Proietti AB, Catalan-Soares BC, Murphy EL. Global epidemiology of HTLV-I infection and associated diseases. Oncogene. 2005;24:6058–6068
  36. Qiu X, Hodges S, Lukaszewska T, Hino S, Arai H, Yamaguchi J, et al. Evaluation of a new, fully automated immunoassay for detection of HTLV-I and HTLV-II antibodies. J. Med. Virol. 2008;80:484–493
  37. Rodgers-Johnson P, Gajdusek DC, Morgan OS, Zaninovic V, Sarin PS, Graham DS. HTLV-I and HTLV-III antibodies and tropical spastic paraparesis. Lancet. 1985;2:1247–1248
  38. Saito M, Vogler IH, Turra MRS, Koti ANJ, Arai KM, Spinosa A-A, Giovenazzi MG, Silva MC (2008) Frequency of positive serologic markers used in the screening of the blood donors of hemocentro regional de Londrina, Parana, Brazil (Period of January 2004 to December 2006). Vox Sang 95(Suppl. 1):141. (Abstract).
  39. Switzer WM, Qari SH, Wolfe ND, Burke DS, Folks TM, Heneine W. Ancient origin and molecular features of the novel human T-lymphotropic virus type 3 revealed by complete genome analysis. J. Virol. 2006;80:7427–7438
  40. Taylor GP, Bodeus M, Courtois F, Pauli G, Del MA, Machuca A, et al. The seroepidemiology of human T-lymphotropic viruses: types I and II in Europe: a prospective study of pregnant women. J. Acquir. Immune Defic. Syndr. 2005;38:104–109
  41. Thorstensson R, Albert J, Andersson S. Strategies for diagnosis of HTLV-I and -II. Transfusion. 2002;42:780–791
  42. Varma M, Rudolph DL, Knuchel M, Switzer WM, Hadlock KG, Velligan M, et al. Enhanced specificity of truncated transmembrane protein for serologic confirmation of human T-cell lymphotropic virus type 1 (HTLV-1) and HTLV-2 infections by western blot (immunoblot) assay containing recombinant envelope glycoproteins. J. Clin. Microbiol. 1995;33:3239–3244
  43. Vrielink H, Reesink H, Habibuw M, Schuller M, van der Meer C, Lelie P. Comparison of four HTLV-I and HTLV-I + II ELISAs. Vox Sang. 1999;76:187–191
  44. Wiley CA, Nerenberg M, Cros D, Soto-Aguilar MC. HTLV-I polymyositis in a patient also infected with the human immunodeficiency virus. N. Engl. J. Med. 1989;320:992–995
  45. Yakova M, Lezin A, Dantin F, Lagathu G, Olindo S, Jean-Baptiste G, et al. Increased proviral load in HTLV-1–infected patients with rheumatoid arthritis or connective tissue disease. Retrovirology. 2005;2:4
  46. Yamaguchi K, Seiki M, Yoshida M, Nishimura H, Kawano F, Takatsuki K. The detection of human T cell leukemia virus proviral DNA and its application for classification and diagnosis of T cell malignancy. Blood. 1984;63:1235–1240
  47. Yoshida M, Miyoshi I, Hinuma Y. Isolation and characterization of retrovirus from cell lines of human adult T-cell leukemia and its implication in the disease. Proc. Natl. Acad. Sci. U. S. A. 1982;79:2031–2035
  48. Zervou F, Karabini F, Ziciadis K, Valari O, Dova L, Tzolou A, Xanthi E, Soukouvelou A, Britsas E, and Xenakis TH (2008) The prevalence of HIV, HBV, HVC, HTLV I/II and syphilis infection among femoral head donors in University Hospital in Northwestern Greece. Vox Sang (Suppl. 1)95:530. (Abstract).
  49. Zweig MH, Campbell G. Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine. Clin. Chem. 1993;39:561–577

PII: S0732-8893(09)00512-4

doi: 10.1016/j.diagmicrobio.2009.12.021

Diagnostic Microbiology & Infectious Disease
Volume 67, Issue 1 , Pages 61-69 , May 2010

Article Tools

* Image Usage & Resolution